-Reuters
Mannkind Corporation Closed Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds
MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8, 2021, of its previously announced sale-leaseback transaction with an affiliate of Creative Manufacturing Prop